Search results for " Ly"

showing 10 items of 2487 documents

Prognostic impact of extra-nodal extension in thyroid cancer: A meta-analysis

2015

Background and Objectives Lymph node involvement is common in thyroid cancer, but the system of staging does not consider the histological features of lymph node metastases. We conducted a meta-analysis to investigate the prognostic role of extranodal extension (ENE) in thyroid cancer patients. Methods We ran PubMed and SCOPUS searches without language restrictions. Prospective studies reporting data on overall mortality, cancer-specific mortality, or disease recurrence including thyroid cancer patients, in which cases with ENE (ENE+) were compared with those with only intranodal disease (ENE-) were eligible. Data were summarized using risk ratios (RR) for number of deaths/recurrences, and …

Oncologyextranodal extension; prognosis; survival; thyroid cancerLymphatic MetastasisMedicine (all)thyroid cancerextranodal extensionHumansSurgeryprognosisThyroid Neoplasmsextranodal extension; prognosis; survival; thyroid cancer; Humans; Lymphatic Metastasis; Prognosis; Thyroid Neoplasms; Surgery; Oncology; Medicine (all)survival: extranodal extension
researchProduct

Extranodal Extension of Nodal Metastases Is a Poor Prognostic Indicator in Gastric Cancer: a Systematic Review and Meta-analysis.

2016

Introduction: The extranodal extension (ENE) of nodal metastases (the extension of neoplastic cells through the nodal capsule into the perinodal soft tissue) is a histological feature that has been considered a prognostic factor in several cancers, but the role in gastric cancer was not yet investigated. We aimed to investigate the prognostic role of ENE in patients affected by gastric cancer through a systematic review and meta-analysis. Material and Methods: Two independent authors searched major databases until 09/30/2015 to identify studies providing data on gastric cancer patients’ prognostic parameters and comparing patients with ENE (ENE+) vs intra-nodal extension (ENE−). The data we…

Oncologymedicine.medical_specialty03 medical and health sciencesNodal Metastases Extranodal Extension Gastric Cancer0302 clinical medicineextranodal extension nodal metastases gastric cancerRecurrenceStomach NeoplasmsInternal medicineExtranodal extensionmedicineOdds RatioHumansGastric cancer . ENE . Extranodal extensionENE; Extranodal extension; Gastric cancer; Lymph node metastasis; Surgery; GastroenterologyProportional Hazards ModelsLymph node metastasisbusiness.industryProportional hazards modelNodal MetastasesHazard ratioConfoundingGastroenterologyCancerOdds ratiomedicine.diseasePrognosisConfidence interval030220 oncology & carcinogenesisMeta-analysisRelative riskLymphatic MetastasisENE030211 gastroenterology & hepatologySurgeryLymph NodesNeoplasm Recurrence LocalbusinessGastric cancerJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
researchProduct

The role of stem cell transplantation in follicular lymphoma.

2017

With the introduction of novel treatments paradigms to if or when to use transplantation strategies for patients with follicular lymphoma have changed substantially. Autologous transplantation has been intensively evaluated as consolidation after first induction treatment with positive effects, however the introduction of Rituximab led to comparable improvements and HDT has been moved to relapse treatment. In this indication HDT was frequently use already at first relapse, but now is dominantly used in patients with a highrisk profile, e.g. failure of response, early or multiply relapse and/or signs of transformation. The ideal place for allogeneic transplantation is even harder to define, …

Oncologymedicine.medical_specialtyAllogeneic transplantationSide effectClinical BiochemistryFollicular lymphomaTransplantation Autologous03 medical and health sciences0302 clinical medicineInternal medicinemedicineAutologous transplantationHumansIn patientPrecision MedicineLymphoma Follicularbusiness.industryHematopoietic Stem Cell Transplantationmedicine.diseaseTransplantationOncology030220 oncology & carcinogenesisRituximabStem cellbusinessRituximab030215 immunologymedicine.drugBest practiceresearch. Clinical haematology
researchProduct

Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group

2021

Haematologica : journal of the European Hematology Association 106(5), 1390-1400 (2021). doi:10.3324/haematol.2019.244780

Oncologymedicine.medical_specialtyArticle03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansCumulative incidence030304 developmental biology0303 health sciencesChildhood Cancer RegistryUnivariate analysisbusiness.industryIncidenceLymphoma Non-HodgkinMyelodysplastic syndromesIncidence (epidemiology)Lymphoblastic lymphomaMyeloid leukemiaNeoplasms Second PrimaryHematologyPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseLymphoma030220 oncology & carcinogenesisFemaleCranial Irradiationbusiness
researchProduct

Cardiovascular Damage Induced by Anti-BCR-ABL TKIs

2018

Anti-BCR-ABL TKIs (tyrosine kinase inhibitors) are drugs that inhibit BCR ABL tyrosine. They are used especially in the treatment of hematological cancer and gastrointestinal stromal tumors (GIST). Anti-BCR-ABL TKIs include first (imatinib), second (nilotinib, dasatinib, bosutinib) and third-generation drugs (ponatinib). Especially second- and third-generation drugs can cause cardiovascular complications such as arterial thrombosis, myocardial ischemia, peripheral arterial diseases, QTc prolongation, and pulmonary hypertension. Nilotinib and ponatinib can cause thrombotic arterial events with various mechanisms. Particularly dasatinib can cause pulmonary hypertension. Compared to convention…

Oncologymedicine.medical_specialtyCardiotoxicitybusiness.industryPonatinibImatinibDasatinibchemistry.chemical_compoundchemistryNilotinibhemic and lymphatic diseasesInternal medicinemedicineAdverse effectbusinessBosutinibTyrosine kinasemedicine.drug
researchProduct

Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cel…

2011

Abstract Abstract 3089 Introduction: High-dose chemotherapy (HDT) and autologous stem-cell transplantation (ASCT) demonstrated high efficacy in the treatment of newly-diagnosed primary CNS lymphoma (PCNSL) in eligible patients (pts). Prognosis of PCNSL is associated with several clinical and histopathological risk factors (RF). Early complete response (CR) during chemotherapy (CHT) was recently reported to be an additional independent prognostic factor in pts undergoing polychemotherapy without HDT+ASCT. In this analysis, we examined the extent to which known RF determined survival in pts who were treated with HDT-ASCT. We additionally investigated the impact of HDT-ASCT specific factors (e…

Oncologymedicine.medical_specialtyChemotherapyPerformance statusbusiness.industryProportional hazards modelmedicine.medical_treatmentImmunologyPrimary central nervous system lymphomaCell BiologyHematologyThioTEPAmedicine.diseaseBiochemistryChemotherapy regimenSurgeryTransplantationInternal medicineMedicineStem cellbusinessmedicine.drugBlood
researchProduct

Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia

2008

Chronic lymphocytic leukemia is an adult-onset leukemia with a heterogeneous clinical behavior. When chronic lymphocytic leukemia cases were divided on the basis of IgVH mutational status, widely differing clinical courses were revealed. Since IgVH sequencing is difficult to perform in a routine diagnostic laboratory, finding a surrogate for IgVH mutational status seems an important priority. In the present study, we proposed the use of Cryptochrome- 1 as a new prognostic marker in early-stage chronic lymphocytic leukemia. Seventy patients (Binet stage A, without treatment) were included in the study. We correlated Cryptochrome-1 mRNA with well established prognostic markers such as IgVH mu…

Oncologymedicine.medical_specialtyChronic lymphocytic leukemiaIgV(H)ZAP70 LPL IgVHImmunoglobulin E:CIENCIAS MÉDICAS ::Patología::Hematología [UNESCO]Prognostic markerPredictive Value of TestsInternal medicinemedicineHumansUNESCO::CIENCIAS MÉDICAS ::Patología::HematologíaRNA MessengerStage (cooking)HematologybiologyFlavoproteinsZAP70CancerHematologyCryptochrome-1medicine.diseasePrognosis:CIENCIAS MÉDICAS [UNESCO]Leukemia Lymphocytic Chronic B-CellCryptochromesLeukemiaUNESCO::CIENCIAS MÉDICAS ::Patología::OncologíaImmunologyUNESCO::CIENCIAS MÉDICASbiology.proteinZAP70Brief ReportsChronic lymphocytic leukemiaAntibodyLPL:CIENCIAS MÉDICAS ::Patología::Oncología [UNESCO]BiomarkersCryptochrome-1 ; Prognostic marker ; Chronic lymphocytic leukemia ; ZAP70 LPL IgVH
researchProduct

Host Genetic Background and Risk of Richter Syndrome: The Genotype of LRP4 Is An Independent Predictor of Chronic Lymphocytic Leukemia Transformation…

2009

Abstract Abstract 2340 Poster Board II-317 Richter syndrome (RS) represents the transformation of chronic lymphocytic leukemia (CLL) to aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). Mechanisms and risk factors of CLL transformation to RS are known only in part. This study aimed at exploring the role of the host genetic background in RS transformation and was based on a consecutive series of 331 CLL, of which 21 had transformed to RS (all clonally related to the CLL clone). Twenty eight additional cases of clonally related RS were also collected for validation purposes. Using an educated guess approach, SNPs were selected according to the following criteria: i) re…

Oncologymedicine.medical_specialtyChronic lymphocytic leukemiaImmunologySingle-nucleotide polymorphismCell BiologyHematologyBiologymedicine.diseaseBiochemistryMinor allele frequencyInternal medicineImmunologyGenotypemedicineSNPAlleleCD5Diffuse large B-cell lymphomaBlood
researchProduct

Tumor budding as a risk factor for nodal metastasis in pT1 colorectal cancers: a meta-analysis

2017

Worldwide, colorectal cancer (CRC) screening programs have significantly increased the detection of submucosal (pT1) adenocarcinoma. Completion surgery may be indicated after endoscopic excision of these potentially metastasizing early cancers. However, the postsurgical prevalence of nodal implants does not exceed 15%, leading to questions concerning the clinical appropriateness of any post–endoscopy surgery. Eastern scientific societies (Japanese Society for Cancer of the Colon-Rectum, in particular) include tumor budding (TB), defined as the presence of isolated single cancer cells or clusters of fewer than 5 cancer cells at the tumor invasive front, among the variables that must be inclu…

Oncologymedicine.medical_specialtyColorectal cancerBiopsyTumor buddingAdenocarcinomaRisk AssessmentPathology and Forensic MedicineColorectal cancer; Lymph node metastasis; Meta-analysis; Sprouting; Tumor buddingColorectal cancer; Lymph node metastasis; Meta-analysis; Sprouting; Tumor budding; Adenocarcinoma; Biopsy; Colorectal Neoplasms; Humans; Lymph Nodes; Lymphatic Metastasis; Neoplasm Invasiveness; Neoplasm Staging; Odds Ratio; Predictive Value of Tests; Risk Assessment; Risk Factors; Cell MovementLymph node metastasi03 medical and health sciences0302 clinical medicineTumor buddingPredictive Value of TestsRisk FactorsCell MovementTumor budding.Internal medicineBiopsymedicineOdds RatioHumansMeta-analysiNeoplasm InvasivenessRisk factorNeoplasm StagingLymph node metastasismedicine.diagnostic_testbusiness.industryCancerOdds ratiomedicine.diseaseColorectal cancerSurgeryMeta-analysis030220 oncology & carcinogenesisPredictive value of testsLymphatic MetastasisAdenocarcinoma030211 gastroenterology & hepatologyLymph NodesbusinessColorectal NeoplasmsSprouting
researchProduct

Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies

2017

Ibrutinib is highly active in treating mantle cell lymphoma (MCL), an aggressive B-cell lymphoma. We pooled data from three ibrutinib studies to explore the impact of baseline patient characteristics on treatment response. Patients with relapsed/refractory MCL (n = 370) treated with ibrutinib had an objective response rate (ORR) of 66% (20% complete response; 46% partial response); median duration of response (DOR), progression-free survival (PFS) and overall survival (OS) were 18.6, 12.8 and 25.0 months, respectively. Univariate analyses showed patients with one versus >one prior line of therapy had longer OS. Multivariate analyses identified that one prior line of therapy affected PFS; Ea…

Oncologymedicine.medical_specialtyECOG Performance StatusAntineoplastic AgentsLymphoma Mantle-CellBlastoidArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternational Prognostic IndexPiperidinesRecurrenceInternal medicinemedicineHumansneoplasmsSurvival analysisUnivariate analysisPerformance statusbiologybusiness.industryAdenineHematologybiology.organism_classificationmedicine.diseaseSurvival AnalysisSurgeryPyrimidinesTreatment Outcomechemistry030220 oncology & carcinogenesisIbrutinibPyrazolesMantle cell lymphomabusiness030215 immunologyBritish Journal of Haematology
researchProduct